Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 137Carcinoma, Non-Small-Cell Lung 38Carcinoma, Renal Cell 33Neoplasm Metastasis 32Prostatic Neoplasms 22Brain Neoplasms 21Lung Neoplasms 20Pancreatic Neoplasms 19Uveal Melanoma 17Neoplasms 17Carcinoma, Hepatocellular 13Breast Neoplasms 13Sarcoma 12Skin Neoplasms 10Kidney Neoplasms 10Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Glioblastoma 9Triple Negative Breast Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Transitional Cell 8Small Cell Lung Carcinoma 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Recurrence 6Multiple Myeloma 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5Rectal Neoplasms 5

Interventions

Proton Therapy 2tazemetostat 1selinexor 1pazopanib 1Zoledronic Acid 1Radiation Dose Hypofractionation 1Protons 1Nivolumab 1Neurofibromin 1 1Ipilimumab 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Nerve Sheath Neoplasms × Ipilimumab × Clear all
NCT04465643 2026-05-29

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
13 enrolled

Nerve Sheath Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡